Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder
Launched by UNIVERSITY OF GÖTTINGEN · Oct 4, 2007
Trial Information
Current as of July 08, 2025
Completed
Keywords
ClinConnect Summary
In continuation of prior work from our group (Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998; 155(5):603-9.) it is the purpose of this trial to test the assumed superiority of a combined therapy of paroxetine and aerobic exercise compared to placebo or unspecific relaxation training in panic disorder. Participants were randomized to a 10 week treatment protocol of paroxetine 40 mg daily or placebo in combination with regular exercise or regular relaxation after having given informed c...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Panic disorder with or without agoraphobia due to DSM-IV
- • Written informed consent
- • Score of 17 or more on the P\&A scale
- • Score on the CGI of 4 or more (markedly ill)
- Exclusion Criteria:
- • Pregnancy, lactating or insufficient contraception (pearl index \>1)
- • Other psychiatric disorders such as psychoses, addictive disorders, dementia, etc.
- • Clinically relevant abnormalities in physical examination or laboratory results
- • Prior major depression or bipolar disorder
- • Suicidality
- • psychotropic medication other than promethazine
- • current psychological treatment
- • unable to perform regular aerobic exercise
About University Of Göttingen
The University of Göttingen, a prestigious research institution located in Germany, is committed to advancing medical science through innovative clinical trials. Renowned for its interdisciplinary approach, the university leverages expertise across various fields to conduct rigorous studies aimed at improving patient outcomes. With a focus on ethical research practices and robust scientific methodologies, the University of Göttingen collaborates with leading healthcare professionals and institutions to explore novel therapeutic strategies and contribute to the global understanding of health and disease. Its dedication to fostering academic excellence and translating research findings into clinical applications positions it as a key player in the advancement of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göttingen, , Germany
Patients applied
Trial Officials
Borwin Bandelow, Prof, MD
Principal Investigator
University of Göttingen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials